about
STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia.Assessment of muscle mass and strength in mice.Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia.Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.STAT3 in the systemic inflammation of cancer cachexia.Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling PathwaysChemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.Caveolinopathies: translational implications of caveolin-3 in skeletal and cardiac muscle disorders.Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α.The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy.Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients.MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis.Muscle myostatin signalling is enhanced in experimental cancer cachexia.Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?IGF-1 is downregulated in experimental cancer cachexiaCachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolismGrowth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexiaChronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles.Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer ProgressionShort-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged miceHCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexiaPDK4 drives metabolic alterations and muscle atrophy in cancer cachexia
P50
Q31028277-A9F94344-3E40-4000-BABC-F0AE209F7BD9Q34626024-605DE7E0-3996-459B-98F4-E6CB6FC7DC68Q35997011-6A90ABA3-FAF2-4964-9D06-3BBC9F1726B8Q36179118-B647F444-19B2-46B3-9FFA-9A81DBF33BC0Q36893329-1D6B2234-9D53-427A-9727-D4917EA4B16EQ36901910-2AAA72C4-AE93-45DA-8FE9-15628E00C3F0Q37350003-CF05136A-7BC5-4D25-9AF2-BBB6FDEDD13BQ37536603-5E42E001-A614-478B-87E6-C92DBCAACAEAQ37865702-9EDEB7E2-CE68-4235-BEC8-E430B03688A9Q39681574-71E1B65E-2655-43E7-BDC5-64B99F14C086Q39860170-F681B0AD-3609-4C5E-B404-881690866168Q43820079-60392574-2EDF-438B-8475-F91B14060239Q44315702-680F3A6C-C35F-41FE-9A3A-365D61422B61Q46519828-0F13D96E-455B-4AB6-937C-D27C2D4BBE2BQ54448314-6D471BEF-D517-420B-A04B-A40BE786EF07Q60403681-2DC9C8BF-143F-4C8F-87E6-C3312583BB49Q64284079-14FB4769-2E86-4D7C-A375-7173989C19E2Q64847268-1A77E69C-EC81-48E6-9231-A2A4C4A14418Q64937507-FC7CCFAE-DB5D-4CBA-BC4F-876432E825D9Q90633066-F144D6E5-E6B5-461B-960A-21747094CA8EQ91562264-FF834AEA-C5E2-4700-A4F0-04B6CBDA6373Q92502076-757942EE-303B-49D4-B633-7F758ED53FB9Q92508234-08A88FA2-E863-4F64-BAA3-D4696006D234
P50
description
researcher ORCID ID = 0000-0002-3235-1871
@en
wetenschapper
@nl
name
Andrea Bonetto
@ast
Andrea Bonetto
@en
Andrea Bonetto
@es
Andrea Bonetto
@nl
type
label
Andrea Bonetto
@ast
Andrea Bonetto
@en
Andrea Bonetto
@es
Andrea Bonetto
@nl
prefLabel
Andrea Bonetto
@ast
Andrea Bonetto
@en
Andrea Bonetto
@es
Andrea Bonetto
@nl
P106
P1153
14518989900
P31
P496
0000-0002-3235-1871